Home » Stocks & Shares » Shire share price: FDA Takhzyro approval boost for Shire

Shire share price: FDA Takhzyro approval boost for Shire

Alison Bishop
  • August 24th 2018, 10:24
  • Last Updated: October 21st 2019, 15:11

Global biotech giant Shire Group (LON:SHP ) has this morning reported  that its innovative preventative treatment for hereditary angiodema, Takhzyro, has received approval from the Food and Drug Administration.Takhzyro is a self administered, sub-cutaneous injection which studies have shown to reduce average monthly attacks by 87 per cent, compared with a placebo group. Furthermore, a significant number of the experimental group suffered from zero attacks during the trial.

The news has impacted positively on Shire’s share price which was up 104.50 (2.36%) as of BST 08.58 to 4527.00 and climbing, overperforming the FTSE which in comparison is marginally up 10.86 (0.14%) at 7574.08, possibly subdued following an escalation in the US/China trade stand off.

Aim for zero attacks

In a press release from the group, Andreas Busch, Phd., Head of Research and Development for the company said, “With the approval of Takhzyro, HAE patients have an innovative treatment that works differently to current options to help prevent attacks. Based on an exploratory and post hoc analysis, after six doses of Takhzyro 300mg every two weeks, 77% or nearly 8 out of 10 patients had zero attacks. This approval reinforces our ongoing commitment to developing novel therapies that have a meaningful impact on patients. Looking to the future we continue to work towards our goal of a world in which those living with HAE can aim for zero attacks.”

Recurring edema can be fatal

HAE is a genetic disorder which is thought to affect somewhere in the region of 1 in 10,000 to 1 in 50,000 people. The condition manifests itself in extremely debilitating, painful, recurring edema which predominantly affects the face,hands and airways, and can be fatal if experienced in the larynx, causing asphyxiation.

In response to the news, as reported by Proactive Investors, Anthony Castaldo, president of the US Hereditory Angiodema Association marked the findings of the study as an : “…important addition to the HAE treatment landscape.”

As of 10:28 BST, Friday, 24 August, Shire PLC share price is 4,777.00p.

About the author

Alison Bishop
Alison is our leading cryptocurrency ICO reporter, boasting a technical development background and over 6 years working with blockchain technology.

Leave a Reply

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.